Navigation Links
EvaluatePharma Appoints Alexander Karle as COO
Date:9/12/2012

LONDON and BOSTON, September 12, 2012 /PRNewswire/ --

EvaluatePharma®, the premier source for life science sector analysis and consensus forecasts, has appointed Alexander Karle as Chief Operating Officer. Karle's experience in formulating customer-centric growth strategies and leading them to successful implementation will be instrumental in driving EvaluatePharma's continued expansion within key industry sectors and geographic markets.

Prior to joining EvaluatePharma, Karle served as Vice President of Strategy and Development for global intelligence firm Thomson Reuters. There, he served on the executive leadership team and was responsible for defining and leading the corporate growth strategy for Thomson Reuters' intellectual property and science division, an $800M+ information and services business. Karle also led the restructuring of Thomson Reuters' pharmaceutical benchmarking business, CMR International, where he set strategy and defined new services to integrate with Thomson Reuters' life sciences business. Karle began his professional career as a Senior Associate at Booz Allen & Hamilton. Karle holds a Bachelor of Arts in business, economics and law from the European Business Programme in Münster, Germany and Hull, United Kingdom as well as a Master of Business Administration from Yale University's School of Management.

"Alexander brings a breadth of experience in driving corporate development for global intelligence firms within the life sciences. His expertise in driving successful operational growth for Thomson Reuters' science and healthcare businesses will be incredibly relevant," said Dr. Jonathan de Pass, EvaluatePharma CEO. "We are thrilled to welcome someone of his caliber to our executive leadership team."

About EvaluatePharma

Since 1996, EvaluatePharma has been the premier source for life science sector analysis, delivering exclusive, trusted commercial insight into industry performance through its proprietary platform. EvaluatePharma is staffed by a team of over 85 dedicated healthcare analysts employing rigorous methodologies to deliver the most-up-to-date commercial performance data available. An award winning editorial team of journalists writing under the EP Vantage name support EvaluatePharma's analysis.  The EvaluatePharma services enable the life science community to make sound business decisions about value and opportunity. For more information please visit http://www.EvaluatePharma.com.

Media Contacts:
EvaluatePharma
Christine Lindgren
+1-617-866-3906
christinel@EvaluatePharma.com

Chempetitive Group
Erik Clausen
+1-858-457-2436
rlear@chempetitive.com


'/>"/>
SOURCE EvaluatePharma Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. EvaluatePharma Names Debbie Paul CEO, Americas to Lead Growth in Key Region
2. AMRI Appoints Michael Nolan Vice President, Chief Financial Officer and Treasurer
3. Insmed Appoints Will Lewis as President and Chief Executive Officer
4. Circassia Appoints Dr Brett Haumann as Chief Medical Officer
5. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
6. Islet Sciences Appoints Dr. Kevan Herold and Dr. Morton Printz to Scientific Advisory Board
7. Ameritox Appoints New CEO, Scott Walton
8. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
9. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
10. Landauer, Inc. Appoints Ronald Zilkowski To Vice President, Corporate Controller And Chief Accounting Officer
11. Henry Schein Appoints Carol Raphael to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA ... drugs market is expected to grow at a CAGR of ... of 38.7% in the second half of the forecast period. The ... 2016 to 2027. The market is estimated at $1,058 million in ... ...
(Date:1/19/2017)... -- James Gilbart , ... 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ...      ... in a supplement to European Oncology & Haematology ... by James Gilbart and Axel ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange , ... to announce that the first five replication studies ... have been published in eLife today. Despite intense ... the first practical evaluation of reproducibility rates that ... studies. Unlike other assessments of reproducibility, the results ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... wellness products to enhance people’s everyday lives, recently attended the January ECRM Trade ... , ATP Science is known for its large range of supplements that keep ...
(Date:1/20/2017)... ... ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in a ... has been life-saving as she has been on the trial for more than six ... ovarian cancer in 2009. She underwent standard chemotherapy but a year later went to ...
(Date:1/20/2017)... ... 20, 2017 , ... Vitamin Well has launched two new ... have been produced in collaboration with Zlatan Ibrahimovic and have been developed to ... a successful launch in Sweden last year, the next generation sports drinks VW+001 ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Angel”: ... the Lord has set out for each of his children. “The Angel” is the ... School of Music in New York City, and impassioned writer. , When asked of ...
(Date:1/20/2017)... ... ... fine examination of how God handles sin, including how to let go of lingering guilt ... over ten long years has been waiting to release this powerful insight about forgiveness that ... serving the Lord for over twenty years, and he has been preaching and teaching the ...
Breaking Medicine News(10 mins):